Skip to main content

Common Dreams. Journalism funded by people, not corporations.

There has never been—and never will be—an advertisement on our site except for this one: without readers like you supporting our work, we wouldn't exist.

No corporate influence. No pay-wall. Independent news and opinion 365 days a year that is freely available to all and funded by those who support our mission: To inform. To inspire. To ignite change for the common good.

Our mission is clear. Our model is simple. If you can, please support our Fall Campaign today.

Support Our Work -- No corporate influence. No pay-wall. Independent news funded by those who support our mission: To inform. To inspire. To ignite change for the common good. Please support our Fall Campaign today.

Photo: Penn State/flickr

Pharmaceutical Extortion: Pay Up, or Die

Group of global cancer experts criticizes exorbitant drug costs that prevent access to life-saving treatments

Andrea Germanos

A group of cancer experts has issued a searing indictment of the "free market economy" principles that allow pharmaceutical companies to reap enormous profits while patients remain hostages to the industry, forced to either pay high drug prices or lose their lives.

In an editorial in Blood, the journal of the American Society of Hematology, over 100 leukemia experts from around the world argue that

Unaffordable drug prices in CML [chronic myelogenous leukemia] may be preventing many patients from accessing these life-saving drugs. [...]

Grateful patients may have become the “financial victims” of the treatment success, having to pay the high price annually to stay alive.

The prices are too high and ultimately "harmful to the sustainability of our national healthcare systems," they write.

While their focus is on CML drugs, the group writes that their findings are indicative of the "spiraling prices of cancer drugs in general." For example, 11 of the 12 cancer-treating drugs the FDA approved in 2012 were priced above $100,000 per year.

A case in point is the drug imatinib, sold by Novartis under the name Glivec, which provided about $4.7 billion in annual revenues in 2012.

The experts write that it was priced at nearly $30,000 per year in 2001 but skyrocketed to $92,000 per year in 2012, even though the original price already included research costs, "new indications were developed and FDA approved," and more people were taking it. Imatinib, they write, "may have set the pace for the rising cost of cancer drugs."

The authors conclude that the Hippocratic Oath of "do no harm" they took compels them to argue against the high prices of these drugs that do harm to and may risk the lives of cancer patients.


Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.

This is the world we live in. This is the world we cover.

Because of people like you, another world is possible. There are many battles to be won, but we will battle them together—all of us. Common Dreams is not your normal news site. We don't survive on clicks. We don't want advertising dollars. We want the world to be a better place. But we can't do it alone. It doesn't work that way. We need you. If you can help today—because every gift of every size matters—please do. Without Your Support We Simply Don't Exist.

'Outrageous and Shameful': Dems May Cut Paid Leave Due to Manchin's Opposition

Decrying the plan, advocacy groups vowed that "the American people are not going to allow that essential human need to be ignored and negotiated away behind closed doors."

Jessica Corbett ·

Open Letter Warns Trump's 'Big Lie' GOP Poses Existential Threat to Democracy

"Now is the time for leaders in all walks of life—for citizens of all political backgrounds and persuasions—to come to the aid of the republic."

Brett Wilkins ·

Ahead of Historic House Hearing, Fresh Big Oil Misinformation Campaign Exposed

"It's always helpful to remember that big fossil fuel companies (besides being overwhelmingly responsible for carbon pollution) are also skeevy disinformation hucksters."

Jessica Corbett ·

'Very Welcome' Progress as Iran Agrees to Restart Talks on Nuclear Deal Sabotaged by Trump

One peace advocate urged all sides to reconvene negotiations "as soon as possible and with renewed urgency" to avert "disastrous" consequences for Iran and the world.

Brett Wilkins ·

House Progressives: 'When We Said These Two Bills Go Together, We Meant It'

"Moving the infrastructure bill forward without the popular Build Back Better Act risks leaving behind working people, families, and our communities."

Andrea Germanos ·

Support our work.

We are independent, non-profit, advertising-free and 100% reader supported.

Subscribe to our newsletter.

Quality journalism. Progressive values.
Direct to your inbox.

Subscribe to our Newsletter.

Common Dreams, Inc. Founded 1997. Registered 501(c3) Non-Profit | Privacy Policy
Common Dreams Logo